Patents Issued in April 19, 2018
-
Publication number: 20180104320Abstract: Methods, pharmaceutical compositions and vaccines comprising an attenuated bacteria that expresses a recall antigen are disclosed for treatment of cancer.Type: ApplicationFiled: April 26, 2016Publication date: April 19, 2018Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.Inventor: Claudia Gravekamp
-
Publication number: 20180104321Abstract: The present invention provides a nucleic acid construct comprising the following structure: A-X-B in which X is a nucleic acid sequence which encodes a cleavage site; and A and B are nucleic acid sequences encoding a first and a second chimeric antigen receptor (CAR), each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, wherein the spacer of the first CAR is different to the spacer of the second CAR and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain; and wherein: (a) the first and/or second CAR comprises an intracellular retention signal; and/or (b) the signal peptide of the first or second CAR comprises one or more mutation(s) such that it has fewer hydrophobic amino acids.Type: ApplicationFiled: April 26, 2016Publication date: April 19, 2018Inventors: Martin Pulé, Shaun Cordoba
-
Publication number: 20180104322Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.Type: ApplicationFiled: December 5, 2017Publication date: April 19, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Philippe Thomas DENOEL, Pierre DUVIVIER, Carine GORAJ
-
Publication number: 20180104323Abstract: The present application relates to immunogenic compositions comprising Type 5 and/or 8 capular polysaccharide or oligosaccharide from S. aureus having between 30-100% O-acetylation. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising Type 5 and/or 8 capsular polysaccharides with 30-100% O-acetylation are also described.Type: ApplicationFiled: December 13, 2017Publication date: April 19, 2018Inventors: Philippe DENOEL, Jan Poolman
-
Publication number: 20180104324Abstract: Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from Streptococcus agalactiae (GBS) serotypes conjugated to carrier proteins.Type: ApplicationFiled: November 21, 2017Publication date: April 19, 2018Applicant: GLAXOSMITHKLIINE BIOLOGICALS SAInventors: Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
-
Publication number: 20180104325Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.Type: ApplicationFiled: September 21, 2017Publication date: April 19, 2018Applicant: University of Washington through its Center for CommercializationInventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
-
Publication number: 20180104326Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.Type: ApplicationFiled: December 21, 2017Publication date: April 19, 2018Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human ServicesInventors: Stephen S. Whitehead, Richard S. Bennett, Brian R. Murphy
-
Publication number: 20180104327Abstract: The present invention provides cells which have a high ability to propagate influenza virus, are suitable for use in production of an influenza virus for preparing a vaccine, and are able to be cultured in vitro, and a method for producing an influenza virus using the cells. That is, the present invention provides cells for producing an influenza virus in which expression of one or more genes that encode proteins involved in an effect of suppressing influenza virus production in a cell is suppressed and the gene is at least one selected from the group including ACTG1 gene and the like, and a method for producing an influenza virus that includes infecting the cells for producing an influenza virus with an influenza virus and then culturing.Type: ApplicationFiled: September 18, 2015Publication date: April 19, 2018Applicant: Japan Science and Technology AgencyInventors: Yoshihiro KAWAOKA, Tokiko WATANABE, Eiryo KAWAKAMI, Shinji WATANABE
-
Publication number: 20180104328Abstract: The present invention is drawn to liquid stable poultry vaccines that comprise a live avian virus. The invention is also drawn to the manufacture of such vaccines and methods of vaccinating animal subjects with these vaccines.Type: ApplicationFiled: October 20, 2017Publication date: April 19, 2018Applicant: Intervet Inc.Inventors: Zhisong Qiao, Stephanie Cook, Kevin O'Connell, Ian Tarpey
-
Publication number: 20180104329Abstract: Emulsifiers for emulsions vaccine formulations and use in water-in-oil emulsion for vaccine formulations as an emulsifier. The emulsifier is an alkoxylated polyol or polyamine which is optionally acyl terminated. There is also provided a method of forming the vaccine formulation. The emulsifiers provide for emulsions which may require less emulsifier than known emulsifiers, and provide stable emulsions.Type: ApplicationFiled: April 4, 2016Publication date: April 19, 2018Applicant: CRODA INTERNATIONAL PLCInventors: Roberta Ondei, Edna Fernandes
-
Publication number: 20180104330Abstract: A nanoparticle comprising at least one sterol, e.g. cholesterol and a component from Quillaja Saponaria Molina (QuilQ) selected from quillaja saponin, characterized in that said nanoparticles do not comprise a phospholipid and in that the sterol molecule is bound by a hydrophobic bond between a hydroxyl group of the sterol and terpene moieties in a Quil A micelle and by an hydrophilic ester bond between a sterol OH? and COOH? or aldehyde groups in the QuilA micelle. It also relates to a composition comprising the nanoparticles, and the use thereof as carriers for amphipathic or hydrophobic molecules and as agents for treatment of cancer. Further, it regards a method for producing the phospholipid-free nanoparticles, a method for the treatment of cancer and a method for assessing the applicability of the cancer treating method.Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Applicant: Moreinx ABInventors: Bror Morein, Saideh Berenjian, Kefei Hu
-
Publication number: 20180104331Abstract: The present disclosure provides, among other things, compositions (e.g., autoantibodies) that inhibit the growth, viability, or mobility of (invasion by) a cancer cell. Also provided are applications, such as therapeutic and diagnostic methods, in which the agents are useful, as well as screening methods for identifying autoantibodies useful in the applications.Type: ApplicationFiled: May 11, 2016Publication date: April 19, 2018Inventors: Andrew J. Ewald, Veena Padmanaban, Livia Casciola-Rosen, Antony Rosen
-
Publication number: 20180104332Abstract: The present invention relates to combinations and pharmaceutical compositions comprising an IGF inhibitor and a chemotherapeutic agent, and their use in treating a proliferative disorder such as cancer (for example a solid cancer such as pancreatic cancer). The invention also provides an IGF inhibitor for use in treating such proliferative disorders in combination with a chemotherapeutic agent, and a chemotherapeutic agent for use in treating such proliferative disorders in combination with an IGF inhibitor and a biomarker for identifying proliferative disorders which have increased responsiveness to the combined treatment.Type: ApplicationFiled: January 15, 2016Publication date: April 19, 2018Inventors: Ainhoa Mielgo Iza, Michael Schmid
-
Publication number: 20180104333Abstract: An object of the present invention is to provide a novel method that is excellent in superovulation induction efficiency. Specifically, it is an object to provide a method giving superior superovulation induction efficiency as compared with conventional methods using equine chorionic gonadotropin (eCG) and human chorionic gonadotropin (hCG). The present invention provides a superovulation inducing method, comprising simultaneously administering anti-inhibin antibody and equine chorionic gonadotropin (eCG), then, administering human chorionic gonadotropin (hCG), to a female mouse.Type: ApplicationFiled: February 19, 2016Publication date: April 19, 2018Inventors: Naomi NAKAGATA, Toru TAKEO
-
Publication number: 20180104334Abstract: The present invention relates to a composition for storing at least one biomolecule, the composition comprising: a. between about 0.2% w/w to about 20.0% w/w of D-(+)-Trehalose dehydrate; and b. between about 0.1% w/w to about 10.0% w/w of D-Mannitol; c. between about 0.01% w/w to 0.3% w/w of polyoxyethylenesorbitan monooleate; and d. between about 1.0 nM to about 500 mM of Sodium Citrate at pH between about 4.0 to about 8.0; and e. between strictly more than about 0% w/w to about 0.5% w/w of preservative solution, said preservative solution comprising: i. between about 1.0% w/w and about 5.0% w/w of 5 Chloro-2 methyl-4-isothiazolin-3-one; and ii. between about 0.1% w/w and about 3.0% w/w 2-Methyl-4-isothiazolin-3-one.Type: ApplicationFiled: May 20, 2016Publication date: April 19, 2018Applicant: MYCARTIS NVInventors: Didier FALCONNET, Lucienne LAGOPOULOS
-
Publication number: 20180104335Abstract: The invention relates to stable, multi-dose liquid compositions containing proteins, in particular, but not exclusively stable antibodies, and to the use of said compositions in therapy, in particular for the subcutaneous delivery of said stable protein.Type: ApplicationFiled: October 31, 2017Publication date: April 19, 2018Inventors: Henrik Parshad, Dorthe Kot Engelund
-
Publication number: 20180104336Abstract: A method of increasing radiation sensitivity of tumor cells in a subject is disclosed. The method includes the step of administering to the subject an effective amount of a glutaminase inhibitor, such as CB-839 or BPTES. A method of treating a tumor in a subject is also disclosed, which includes the steps of administering to the subject an effective amount of a glutaminase inhibitor and exposing the tumor to radiation in a dose effective to reduce a size of the tumor.Type: ApplicationFiled: October 13, 2017Publication date: April 19, 2018Inventors: Gunnar Boysen, Robert J. Griffin
-
Publication number: 20180104337Abstract: The present invention concerns methods and compositions related to T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. In aspects of the invention, T cells that are CD70-specific are employed. In particular aspects, there are T cells expressing a novel molecule that comprises the full-length CD70 receptor (CD27) fused to the zeta signaling domain of the T-cell receptor complex. Such T cells recognized CD70-positive tumor cells and have cytolytic activity against CD70-positive cancer cells.Type: ApplicationFiled: September 6, 2017Publication date: April 19, 2018Inventors: Stephen M.G. Gottschalk, Donald R. Shaffer, David M. Spencer
-
Publication number: 20180104338Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.Type: ApplicationFiled: December 18, 2017Publication date: April 19, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Joseph TERRACCIANO, Nicole Miller DAMOUR, Chun JIANG, Giovanni FOGLIATO, Giuseppe Alessandron DONADELLI, Dario RESEMINI
-
Publication number: 20180104339Abstract: A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric.Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Applicant: Arjuna Natural Extracts, Ltd.Inventor: Benny Antony
-
Publication number: 20180104340Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid and bupivacaine in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.Type: ApplicationFiled: December 6, 2017Publication date: April 19, 2018Inventors: Hui Rong Shen, Na Gan
-
Publication number: 20180104341Abstract: Pharmaceutical formulations containing lipoic acid derivatives and ion pairs thereof are described. The pharmaceutical formulations are useful in the treatment of medical disorders, such as cancer.Type: ApplicationFiled: July 28, 2017Publication date: April 19, 2018Inventors: Robert G. L. Shorr, Robert J. Rodriguez, Rajinder Bhasin
-
Publication number: 20180104342Abstract: Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).Type: ApplicationFiled: May 12, 2017Publication date: April 19, 2018Applicant: Arbutus Biopharma CorporationInventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, David Butler, Michael E. Jung
-
Publication number: 20180104343Abstract: A method for treating tumor or inflammation in a patient in need thereof by administering a pH sensitive drug which includes a pH sensitive carrier including at least one amphipathic substance, and a physiologically active substance supported in the pH sensitive carrier to induce the pH sensitive carrier to develop a membrane disruptive function and to deliver the physiologically active substance to the site.Type: ApplicationFiled: November 17, 2017Publication date: April 19, 2018Applicant: TERUMO KABUSHIKI KAISHAInventor: Naoki Sakaguchi
-
Publication number: 20180104344Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.Type: ApplicationFiled: July 20, 2017Publication date: April 19, 2018Inventor: Edward T. Maggio
-
Publication number: 20180104345Abstract: Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 ?m. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.Type: ApplicationFiled: October 24, 2017Publication date: April 19, 2018Inventors: Lawrence T. BONI, Brian S. MILLER, Vladimir MALININ, Xingong LI
-
Publication number: 20180104346Abstract: This invention discloses a bioadhesive boric acid formulation and its preparation method. Specifically, preferred vaginal bioadhesive boric acid formulation mainly comprises chitosan, carbopol 974 , polycarbophil, boric acid, and purified water as a gel. The main performance characteristic of this vaginal boric acid preparation is the ability of the formulation to retain and release boric acid in the vagina by using a combination of carbopol 974 and polycarbophil as preferred bioadhesive polymers. It was proved experimentally that boric acid as the antibacterial component of this gel can be maintained at a relatively high concentration (>10 mg/mL) in vagina for an extended period of time (>2 hours) with the use of a combination of polyacrylic acid polymers, i.e. carbopol 974 and polycarbophil.Type: ApplicationFiled: October 15, 2016Publication date: April 19, 2018Inventors: Yu Hui, Xudong Yuan, Tian Zhang
-
Publication number: 20180104347Abstract: The invention provides a nano-sized particle comprising a cross-linked polymer, wherein the polymer is selected from the group consisting of a polyacrylic acid homopolymer; polymethacrylic acid homopolymer; poly(alkylcyanoacrylate) polymer; a copolymer comprising at least two monomers selected from acrylic acid, methacrylic acid, hydroxyethyl acrylate, hydroxyethyl methacrylate, and alkyl cyanoacrylate/cyanoacrylic acid monomers; carboxymethyl cellulose; alginic acid polymer, polylactic-polyglycolic acid (PLGA), and xanthan gum; and wherein said polymer is cross-linked with a metal ion. A process for preparing such particles is also provided.Type: ApplicationFiled: January 5, 2016Publication date: April 19, 2018Inventor: Amnon Sintov
-
Publication number: 20180104348Abstract: A hydrogel composition includes: (1) a polymer network including a first water-soluble polymer and a second water-soluble polymer that are crosslinked through dynamic bonds; and (2) a catalyst to modulate a rate of exchange of crosslinking of the polymer network.Type: ApplicationFiled: October 12, 2017Publication date: April 19, 2018Inventors: Yan Xia, Junzhe Lou, Ovijit Chaudhuri
-
Publication number: 20180104349Abstract: Provided in the present invention is a linker and a preparation method thereof, wherein one end of the linker may covalently link a small molecule compound and the like and the other end may specifically and covalently link a targeting substance site under the action of Sortase enzyme. The linker of the present invention can be used to prepare a targeting drug conjugate.Type: ApplicationFiled: April 28, 2014Publication date: April 19, 2018Inventor: Gang QIN
-
Publication number: 20180104350Abstract: The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.Type: ApplicationFiled: December 14, 2017Publication date: April 19, 2018Applicant: Graybug Vision, Inc.Inventors: Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
-
Publication number: 20180104351Abstract: The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.Type: ApplicationFiled: October 31, 2017Publication date: April 19, 2018Inventors: Romas Alvydas Kudirka, Aaron Edward Albers, Robyn M. Barfield, David Rabuka
-
Publication number: 20180104352Abstract: The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Publication number: 20180104353Abstract: The present invention relates to ligand-targeted molecules and ligand drug conjugates (LDCs) comprising a ligand connected to a functional group, which is connected to a linker, with in turn is bonded to a drug. The LDCs of the present invention also comprise platinum coordination complex wherein the platinum is connected to the linker through monocarboxylato and O—*Pt coordinate bonds. The present invention also relates to methods for preparing these ligand drug conjugates. The present invention further relates to methods for the treatment of tumours using the ligand drug conjugates of the present invention.Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Applicant: INVICTUS ONCOLOGY PVT. LTD.Inventors: Shiladitya SENGUPTA, Sazid HUSSAIN, Dipankar PRAMANIK, Monideepa ROY, Seikh Samad HOSSAIN
-
Publication number: 20180104354Abstract: Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain (TID). The switch may further comprise a linker. Further disclosed herein are methods of using the switches for the treatment of one or more conditions or diseases in a subject in need thereof.Type: ApplicationFiled: July 7, 2017Publication date: April 19, 2018Inventors: Chanhyuk Kim, Travis Young, Yu Cao, Jennifer Ma, Minsoo Kim, Stephanie A. Pinkerton, Peter G. Schultz
-
Publication number: 20180104355Abstract: The present disclosure provides methods for treatment of bladder cancer. The methods include administering an immunoconjugate to a subject in a dosing regimen that includes an induction phase with twice weekly followed by once weekly dosing, and optionally a maintenance phase. The immunoconjugates useful in the methods provided include immunoconjugates having a binding protein that specifically binds to Ep-CAM and a toxin molecule.Type: ApplicationFiled: March 11, 2016Publication date: April 19, 2018Inventors: Glen MACDONALD, Stephen HURLY
-
Publication number: 20180104356Abstract: The present disclosure provides compositions and methods for treatment of bladder cancer. The methods include administering an immunoconjugate having a binding protein that specifically binds to Ep-CAM and a toxin to a subject in need of treatment for bladder cancer.Type: ApplicationFiled: March 11, 2016Publication date: April 19, 2018Inventors: Glen MACDONALD, Stephen HURLY
-
Publication number: 20180104357Abstract: The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2.Type: ApplicationFiled: September 22, 2017Publication date: April 19, 2018Inventors: John Rudge, Frank Delfino, Lauric Haber, Eric Smith, Jessica R. Kirshner, Alison Crawford, Thomas Nittoli
-
Publication number: 20180104358Abstract: Angelman Syndrome (AS) is a genetic disorder occurring in approximately one in every 15,000 births. It is characterized by severe mental retardation, seizures, difficulty speaking and ataxia. The gene responsible for AS was discovered to be UBE3A and encodes for E6-AP, an ubiquitin ligase. A unique feature of this gene is that it undergoes maternal imprinting in a neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene, although other cases are the result of uniparental disomy or mismethylation of the maternal gene. While most human disorders characterized by severe mental retardation involve abnormalities in brain structure, no gross anatomical changes are associated with AS. We have generated a Ube3a protein with additional sequences that should allow the secretion from cells and uptake by neighboring neuronal cells. This would confer a functional E6-AP protein into the neurons and rescue disease pathology.Type: ApplicationFiled: November 7, 2017Publication date: April 19, 2018Applicant: University of South FloridaInventors: Kevin Ron Nash, Edwin John Weeber, Jennifer Leigh Daily
-
Publication number: 20180104359Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecules of interest. The disclosure relates to nucleic acid constructs, such as expression vectors, containing a modified replicon RNA which includes a modified 5?-unstranslated region (5?-UTR) and, optionally, at least some of its original viral sequence encoding structural proteins having been deleted. Also disclosed are methods for producing polypeptides of interest.Type: ApplicationFiled: October 3, 2017Publication date: April 19, 2018Inventor: Kurt Iver Kamrud
-
Publication number: 20180104360Abstract: Method of lowering low-density lipoprotein cholesterol or preventing a cardiac event in a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent, involving administering to the subject a prophylactically effective amount of an RNAi agent. Also, a method of preventing development of atherosclerotic cardiovascular disease in a subject involving administering to the subject a prophylactically effective amount of an RNAi agent. Further, a method of treating a subject who has atherosclerotic cardiovascular disease or who is atherosclerotic cardiovascular disease risk equivalent involving administering to the subject a therapeutically effective amount of an RNAi agent.Type: ApplicationFiled: October 18, 2017Publication date: April 19, 2018Inventors: Peter Wijngaard, David Kallend
-
Publication number: 20180104361Abstract: A dye molecule having the structure (I): where R1 is an SO3? group bound to a hydrogen H atom or to another atom or to an ammonium NH4 group or to a lysine salt or to an arginine salt or to a different monovalent cation, and R2 is an SO3? group, in particular for making dye preparations for use in methods for the treatment of the bodies of humans or animals, for example for dyeing the internal limiting membrane ILM and/or epiretinal membranes EPRM in a surgical method which involves subsequent removal respectively of the ILM and/or of the EPRM; as well as a dye preparation having a density higher than 1.01 g/cm3 and comprising at least one dye and at least one agent for increasing its density which is a polymer with the empirical formula (C12H22O11.C3H5ClO)n, and structure (II).Type: ApplicationFiled: May 25, 2016Publication date: April 19, 2018Inventors: MAURO BECCARO, ENRICO BETTINI, PAOLO SIGNORI
-
Publication number: 20180104362Abstract: The invention provides methods for pre- and intra-operatively localizing penile sentinel lymph nodes by injection of fluorescent dyes into penile tumors.Type: ApplicationFiled: May 31, 2017Publication date: April 19, 2018Applicant: NOVADAQ TECHNOLOGIES ULCInventors: Dragan GOLIJANIN, Lukasz BRZOZOWSKI, Ronald WOOD
-
Publication number: 20180104363Abstract: A coupling agent composition is provided and includes a plurality of non-toxic components and a thickening agent. The plurality of non-toxic components is derived from one or more natural resource materials and is an amount equal to or greater than 97 weight percent (wt %) of the composition. The thickening agent is provided in an amount of 0.05-5.00 wt % of the composition. The balance of the composition is incidental impurities.Type: ApplicationFiled: October 19, 2016Publication date: April 19, 2018Applicant: HR Pharmaceuticals, Inc.Inventors: Jon Wiesman, George Deckner
-
Publication number: 20180104364Abstract: There is provided herein, a texaphyrin-phospholipid conjugate, wherein the texaphyrin-phospholipid conjugate comprises a texaphyrin, texaphyrin derivative or texaphyrin analog covalently attached to a lipid side chain of a phospholipid.Type: ApplicationFiled: April 14, 2016Publication date: April 19, 2018Inventors: Gang ZHENG, Joseph KECA
-
Publication number: 20180104365Abstract: The present invention provides radiolabeled trimethoprim which are useful in imaging tests such as PET scans. The compounds show robust bacterial uptake in vitro and identify infections from inflammation or tumor when administered to a subject. The compounds show rapid and sensitive detection of Ec DHFR containing tumors from control tumors and background tissue. In one aspect, a compound having the structure of formula (I) is provided or a pharmaceutically acceptable salt or prodrug thereof, wherein R is defined herein. Also provided are compositions containing these compounds, positron emission tomography reporter probe comprising these compounds, and methods of imaging a bacterial infection, tracking or monitoring bacteria, distinguishing a bacterial infection from inflammation or tumor, monitoring genetically fused protein expression, and monitoring genetically engineered cells in clinical scenarios such as immunotherapy for cancer treatment.Type: ApplicationFiled: May 10, 2016Publication date: April 19, 2018Inventors: Mark SELLMYER, Robert H. MACH, David A. MANKGFF, lljung LEE
-
Publication number: 20180104366Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression.Type: ApplicationFiled: May 24, 2016Publication date: April 19, 2018Applicant: IsoTherapeutics Group, LLCInventors: R. Keith Frank, Jaime Simon, Kelli R. Jay
-
Publication number: 20180104367Abstract: A solution in which an ultraviolet radiation source is mounted on a flexible substrate is provided. The flexible substrate is capable of having a deformation curvature of at least 0.1 inverse meters. The flexible substrate may be incorporated within an existing enclosure or included in the enclosure. The flexible substrate can be utilized as part of a solution for disinfecting one or more items located within the enclosure. In this case, while the items are within the enclosure, ultraviolent radiation is generated and directed at the items. Wiring for the ultraviolet radiation source can be embedded within the flexible substrate and the flexible substrate can have at least one of: a wave-guiding structure, an ultraviolet absorbing surface, or an ultraviolet reflective surface. A control system can be utilized to manage generation of the ultraviolet radiation within the enclosure.Type: ApplicationFiled: December 15, 2017Publication date: April 19, 2018Applicant: Sensor Electronic Technology, Inc.Inventors: Timothy James Bettles, Alexander Dobrinsky, Michael Shur, Remigijus Gaska
-
Publication number: 20180104368Abstract: A system for sterilizing at least one surface of an object is provided. The system includes a set of ultraviolet radiation sources and a set of wave guiding structures configured to direct ultraviolet radiation having a set of target attributes to a desired location on at least one surface of the object. The set of wave guiding structures can include at least one ultraviolet reflective surface having an ultraviolet reflection coefficient of at least thirty percent. Furthermore, the system can include a computer system for operating the ultraviolet radiation sources to deliver a target dose of ultraviolet radiation to the at least one target surface of the object.Type: ApplicationFiled: December 19, 2017Publication date: April 19, 2018Applicant: Sensor Electronic Technology, Inc.Inventors: Alexander Dobrinsky, Michael Shur
-
Publication number: 20180104369Abstract: A safety cabinet is capable of preventing ozone gas from leaking out of a working chamber during decontamination and circulating the ozone gas in the working chamber to decontaminate the working chamber. The safety cabinet includes a cabinet main body; a shutter that allows opening/closing of an opening part communicatively connecting to a working chamber; an exhaust path through which gas is exhausted from the working chamber; an exhaust valve that is provided in the exhaust path; an air supply and circulating fan that is provided in the working chamber; an ozone generator that introduces ozone gas into the working chamber; a control part that controls the exhaust valve; an air supply and circulating fan; and airtightly closing device that allows the shutter to airtightly close the opening part are included.Type: ApplicationFiled: July 7, 2016Publication date: April 19, 2018Applicants: AIRTECH JAPAN, LTD., TAMURA TECO CO., LTD.Inventors: Naoki WATANABE, Raku SHU, Kozo TAMURA, Hiroyuki NISHIZAWA